Green and Johnson et al. reported there were a few biological factors known to adversely impact the prognosis of DLBCL patients, including the cell-of-origin, co-expression of MYC/BCL2 and co-occurrence of MYC and BCL2/BCL6 rearrangements failed to predict poorer prognosis in limited stage DLBCL(Green et al., 2012; Johnson et al., 2012). The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.